AP NEWS

Librede Inc. Receives Patent for Cannabidiolic Acid (CBDA) Production in Yeast

July 24, 2018

CARLSBAD, Calif.--(BUSINESS WIRE)--Jul 24, 2018--Librede, a leader in natural cannabinoid biosynthesis, has been granted a new patent for the production of cannabidiolic acid (CBDA) in microorganisms. The patent, Production of Cannabidiolic Acid in Yeast, describes the modification of yeast to produce CBDA from simple feedstocks such as sugar. CBDA is a naturally occurring cannabinoid found in hemp and cannabis which is used to produce cannabidiol (CBD). Cannabidiol has been shown to have a wide range of therapeutic properties, including treatment of epilepsy, for which a CBD-based therapeutic has won recent FDA approval. Librede’s fermentation-based cannabinoid production platform has demonstrated that natural CBD can be produced outside of the cannabis plant using yeast, in a process that is similar to making beer. Librede is now in the process of continuing technology development through optimization and scaling for industrial production in large fermenters. Dr. Anthony Farina, Librede’s Chief Scientific Officer, explains: “We have been building our platform around the natural biochemistry in the cannabis plant that gives rise to a diverse set of compounds, with our focus being on therapeutic applications. Having engineered cannabidiol synthesis in the laboratory, we are now beginning the process of scaled up production.”

Fermentation for the production of high value, complex, natural products offers a preferred route to synthesis at an industrial scale. Librede’s biosynthetic approach has several potential advantages over agricultural-based methods including protection from supply volatility, improved consistency, reduced cost, and lower environmental impact. Dr. Jason Poulos, CEO of Librede, explains: “The use of fermentation to produce these compounds represents the future of industrial scale cannabinoid production. As more cannabinoids are shown to have therapeutic value, we must find a way to produce these compounds in a sustainable way. Utilizing the synthetic power of biology allows us economical access to these compounds while minimizing environmental impacts. The future of all cannabinoid production may not be large farm fields but instead compact and highly efficient fermenters.”

About Librede:

Librede is a synthetic biology company that uses biologically-based approaches to produce high value natural products with a focus on cannabinoids. Librede’s patented yeast-based cannabinoid production platform can provide therapeutic cannabinoids to diverse markets in an economically and environmentally sustainable way.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180724005003/en/

CONTACT: Librede

Dr. Jason Poulos, Ph.D.

Chief Executive Officer

poulos@librede.com

www.librede.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH ALTERNATIVE MEDICINE BIOTECHNOLOGY FITNESS & NUTRITION MENTAL HEALTH PHARMACEUTICAL RESEARCH FDA SCIENCE

SOURCE: Librede

Copyright Business Wire 2018.

PUB: 07/24/2018 05:00 AM/DISC: 07/24/2018 05:00 AM

http://www.businesswire.com/news/home/20180724005003/en

AP RADIO
Update hourly